Zixuan Yuan1,2, Liang Zhao1,2, Yafei Zhang3, Shun Li1,2, Bomin Pan1,2, Lei Hua1,2, Zhen Wang1,2, Chengkun Ye1,2, Jun Lu4, Rutong Yu5,6, Hongmei Liu7,8. 1. Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, People's Republic of China. 2. Brain Hospital, Affiliated Hospital of Xuzhou Medical University, 99 West Huai-hai Road, Xuzhou, 221002, Jiangsu, People's Republic of China. 3. General Hospital of Xuzhou Mining Group, Xuzhou, Jiangsu, People's Republic of China. 4. Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province, School of Life Science, Jiangsu Normal University, Xuzhou, Jiangsu, People's Republic of China. lu-jun75@163.com. 5. Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, People's Republic of China. yu.rutong@163.com. 6. Brain Hospital, Affiliated Hospital of Xuzhou Medical University, 99 West Huai-hai Road, Xuzhou, 221002, Jiangsu, People's Republic of China. yu.rutong@163.com. 7. Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, People's Republic of China. liuhongmei816@sina.com. 8. Brain Hospital, Affiliated Hospital of Xuzhou Medical University, 99 West Huai-hai Road, Xuzhou, 221002, Jiangsu, People's Republic of China. liuhongmei816@sina.com.
Abstract
PURPOSE: GOLPH3 has been shown to be involved in glioma proliferation. In this study, we aimed to demonstrate that GOLPH3 can serve as a target for glioma gene therapy. METHODS: During the experiment, cationic liposomes with angiopep-2 (A2-CL) were used to deliver siGOLPH3 crossing the blood-brain barrier and reaching the glioma. RESULTS: At the cellular level, the A2-CL/siGOLPH3 could silence GOLPH3 and then effectively inhibited the proliferation of cells. In vivo experiments, using U87-GFP-Luci-bearing BALB/c mouse models, we demonstrated that A2-CL could deliver GOLPH3-siRNA specifically to glioma and effectively inhibit glioma growth. CONCLUSIONS: This study shows that GOLPH3 has great potential as a target for the gene therapy of glioma and is of great value in precise medical applications.
PURPOSE:GOLPH3 has been shown to be involved in glioma proliferation. In this study, we aimed to demonstrate that GOLPH3 can serve as a target for glioma gene therapy. METHODS: During the experiment, cationic liposomes with angiopep-2 (A2-CL) were used to deliver siGOLPH3 crossing the blood-brain barrier and reaching the glioma. RESULTS: At the cellular level, the A2-CL/siGOLPH3 could silence GOLPH3 and then effectively inhibited the proliferation of cells. In vivo experiments, using U87-GFP-Luci-bearing BALB/c mouse models, we demonstrated that A2-CL could deliver GOLPH3-siRNA specifically to glioma and effectively inhibit glioma growth. CONCLUSIONS: This study shows that GOLPH3 has great potential as a target for the gene therapy of glioma and is of great value in precise medical applications.
Authors: Zvi R Cohen; Srinivas Ramishetti; Naama Peshes-Yaloz; Meir Goldsmith; Anton Wohl; Zion Zibly; Dan Peer Journal: ACS Nano Date: 2015-01-08 Impact factor: 15.881
Authors: Tyler E Miller; Brian B Liau; Lisa C Wallace; Andrew R Morton; Qi Xie; Deobrat Dixit; Daniel C Factor; Leo J Y Kim; James J Morrow; Qiulian Wu; Stephen C Mack; Christopher G Hubert; Shawn M Gillespie; William A Flavahan; Thomas Hoffmann; Rohit Thummalapalli; Michael T Hemann; Patrick J Paddison; Craig M Horbinski; Johannes Zuber; Peter C Scacheri; Bradley E Bernstein; Paul J Tesar; Jeremy N Rich Journal: Nature Date: 2017-07-05 Impact factor: 49.962
Authors: Monique C P Mendonça; Ayse Kont; Maria Rodriguez Aburto; John F Cryan; Caitriona M O'Driscoll Journal: Mol Pharm Date: 2021-03-18 Impact factor: 4.939